This case-control study investigates the positivity rates of the most prevalent neuroglial surface antibodies during the COVID-19 pandemic.
10.1001/jamaneurol.2022.5346
Journal article
JAMA Neurology
American Medical Association (AMA)
01/04/2023
80
419 - 419